To determine whether i.v. administration of DSP-0509 has superior anti-tumor activity against distal tumor compared to topical use of TLR7 agonist, CT26 cells were injected at both dorsal flanks, defined as “primary” and “secondary” tumor. Here, TLR7 is linked to neoplasm.